Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 6 (2009), Issue 6 (June)

1. Targeting innate immunity protein kinase signalling in inflammation.
   Nat Rev Drug Discov, 8(6): 480-99. [Abstract] [Full-text]
2. Parental misinterpretations of over-the-counter pediatric cough and cold medication labels.
   Pediatrics, 123(6): 1464-71. [Abstract] [Full-text]
3. Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
   Cancer Chemother Pharmacol, 64(2): 407-12. [Abstract] [Full-text]
4. Antibiotic prophylaxis for the prevention of infection after major limb amputation.
   Eur J Vasc Endovasc Surg, 37(6): 696-703. [Abstract] [Full-text]
5. Low-molecular-weight dendrons for DNA binding and release by reduction-triggered degradation of multivalent interactions.
   Chemistry, 15(23): 5656-60. [Abstract] [Full-text]
6. Encapsulation and sustained release of curcumin using superparamagnetic silica reservoirs.
   Chemistry, 15(23): 5661-5. [Abstract] [Full-text]
7. Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experience.
   Int J Radiat Oncol Biol Phys, 74(3): 774-80. [Abstract] [Full-text]
8. A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer.
   Cancer Chemother Pharmacol, 64(2): 371-7. [Abstract] [Full-text]
9. A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma.
   Cancer Chemother Pharmacol, 64(2): 379-84. [Abstract] [Full-text]
10. Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer.
    Cancer Chemother Pharmacol, 64(2): 385-90. [Abstract] [Full-text]
11. Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial.
    Cancer Chemother Pharmacol, 64(2): 401-6. [Abstract] [Full-text]
12. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
    Cancer Chemother Pharmacol, 64(2): 361-9. [Abstract] [Full-text]
13. A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer.
    Cancer Chemother Pharmacol, 64(2): 347-53. [Abstract] [Full-text]
14. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
    Cancer Chemother Pharmacol, 64(2): 355-60. [Abstract] [Full-text]
15. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
    Cancer Chemother Pharmacol, 64(2): 327-33. [Abstract] [Full-text]
16. Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.
    Cancer Chemother Pharmacol, 64(2): 301-6. [Abstract] [Full-text]
17. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study.
    Cancer Chemother Pharmacol, 64(2): 317-25. [Abstract] [Full-text]
18. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
    Cancer Chemother Pharmacol, 64(2): 233-41. [Abstract] [Full-text]
19. Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy.
    Cancer Chemother Pharmacol, 64(2): 271-7. [Abstract] [Full-text]
20. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT.
    J Photochem Photobiol B, 96(1): 1-8. [Abstract] [Full-text]
21. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
    Cancer Lett, 280(2): 184-91. [Abstract] [Full-text]
22. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma.
    Ann Surg, 249(6): 1008-13. [Abstract] [Full-text]
23. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
    Am J Psychiatry, 166(6): 691-701. [Abstract] [Full-text]
24. Measuring the quality of medication use in older adults.
    J Am Geriatr Soc, 57(6): 1096-102. [Abstract] [Full-text]
25. Potentially inappropriate medications and functional decline in elderly hospitalized patients.
    J Am Geriatr Soc, 57(6): 1007-14. [Abstract] [Full-text]
26. Comparative chlorpyrifos pharmacokinetics via multiple routes of exposure and vehicles of administration in the adult rat.
    Toxicology, 261(1): 47-58. [Abstract] [Full-text]
27. Flexible polymerosomes--an alternative vehicle for topical delivery.
    Colloids Surf B Biointerfaces, 72(1): 161-6. [Abstract] [Full-text]
28. A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women.
    Psychoneuroendocrinology, 34(7): 1065-74. [Abstract] [Full-text]
29. Facial paralysis after superselective intra-arterial chemotherapy via the middle meningeal artery in maxillary cancer.
    Auris Nasus Larynx, 36(4): 479-81. [Abstract] [Full-text]
30. Chitosan-chondroitin sulfate based matrix tablets for colon specific delivery of indomethacin.
    AAPS PharmSciTech, 10(2): 670-7. [Abstract] [Full-text]
31. Conjugated oral versus transdermal estrogen replacement in girls with Turner syndrome: a pilot comparative study.
    J Clin Endocrinol Metab, 94(6): 2009-14. [Abstract] [Full-text]
32. Bone mineral density, growth, and thyroid function in long-term survivors of pediatric Hodgkin's lymphoma treated with chemotherapy only.
    J Clin Endocrinol Metab, 94(6): 1904-9. [Abstract] [Full-text]
33. A modular diffusion barrier based on phase separation for localized delivery of discrete drug volumes in aqueous environments.
    Lab Chip, 9(12): 1801-5. [Abstract] [Full-text]
34. A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
    Br J Cancer, 100(11): 1725-30. [Abstract] [Full-text]
35. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
    Br J Cancer, 100(11): 1720-4. [Abstract] [Full-text]
36. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer.
    Gynecol Oncol, 114(1): 37-41. [Abstract] [Full-text]
37. Case report: Recurrence of a uterine tumor resembling ovarian sex-cord tumor.
    Gynecol Oncol, 114(1): 140-2. [Abstract] [Full-text]
38. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
    Gynecol Oncol, 114(1): 94-8. [Abstract] [Full-text]
39. Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer.
    Gynecol Oncol, 114(1): 42-7. [Abstract] [Full-text]
40. Self-assembly of pH-responsive fluorinated dendrimer-based particulates for drug delivery and noninvasive imaging.
    Biomaterials, 30(23): 3946-55. [Abstract] [Full-text]
41. In-vitro osteogenesis of synovium stem cells induced by controlled release of bisphosphate additives from microspherical mesoporous silica composite.
    Biomaterials, 30(23): 3996-4005. [Abstract] [Full-text]
42. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors.
    Biomaterials, 30(23): 3986-95. [Abstract] [Full-text]
43. Direct formation of proteo-liposomes by in vitro synthesis and cellular cytosolic delivery with connexin-expressing liposomes.
    Biomaterials, 30(23): 3971-7. [Abstract] [Full-text]
44. In vivo evaluation of vaginal films for mucosal delivery of nitric oxide.
    Biomaterials, 30(23): 3978-85. [Abstract] [Full-text]
45. Mixed micelle systems formed from critical micelle concentration and temperature-sensitive diblock copolymers for doxorubicin delivery.
    Biomaterials, 30(23): 3961-70. [Abstract] [Full-text]
46. Group B streptococcus and early-onset sepsis in the era of maternal prophylaxis.
    Pediatr Clin North Am, 56(3): 689-708, Table of Contents. [Abstract] [Full-text]
47. Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients.
    Metabolism, 58(7): 927-33. [Abstract] [Full-text]
48. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad.
    Clin Infect Dis, 49(1): 155-9. [Abstract] [Full-text]
49. Improved survival in patients with breast rhabdoid tumors with multi-agent adjuvant chemotherapy combined with irradiation.
    Cancer Chemother Pharmacol, 64(3): 623-7. [Abstract] [Full-text]
50. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
    Cancer Chemother Pharmacol, 64(3): 549-55. [Abstract] [Full-text]
51. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Cancer Chemother Pharmacol, 64(3): 565-73. [Abstract] [Full-text]
52. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
    Cancer Chemother Pharmacol, 64(3): 445-54. [Abstract] [Full-text]
53. A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.
    Cancer Chemother Pharmacol, 64(3): 455-62. [Abstract] [Full-text]
54. Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma.
    Cancer Chemother Pharmacol, 64(3): 497-507. [Abstract] [Full-text]
55. Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model.
    Cancer Lett, 281(1): 53-63. [Abstract] [Full-text]
56. Molecular targeted treatment and radiation therapy for rectal cancer.
    Strahlenther Onkol, 185(6): 371-8. [Abstract] [Full-text]
57. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.
    J Clin Oncol, 27(17): 2838-47. [Abstract] [Full-text]
58. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
    J Clin Oncol, 27(17): 2848-54. [Abstract] [Full-text]
59. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
    J Clin Oncol, 27(17): 2823-30. [Abstract] [Full-text]
60. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
    J Clin Oncol, 27(17): 2772-8. [Abstract] [Full-text]
61. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
    J Clin Oncol, 27(17): 2863-73. [Abstract] [Full-text]
62. Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer.
    J Clin Oncol, 27(17): 2816-22. [Abstract] [Full-text]
63. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    J Antimicrob Chemother, 64(1): 118-25. [Abstract] [Full-text]
64. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
    J Antimicrob Chemother, 64(1): 126-34. [Abstract] [Full-text]
65. Effects of intranasally applied dopamine on behavioral asymmetries in rats with unilateral 6-hydroxydopamine lesions of the nigro-striatal tract.
    Neuroscience, 162(1): 174-83. [Abstract] [Full-text]
66. Dynamics of magnetic lipoplexes studied by single particle tracking in living cells.
    J Control Release, 137(2): 136-45. [Abstract] [Full-text]
67. A fast screening strategy for characterizing peptide delivery by transdermal iontophoresis.
    J Control Release, 137(2): 123-9. [Abstract] [Full-text]
68. Design and evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for sustained pharmacological response.
    J Control Release, 137(2): 152-9. [Abstract] [Full-text]
69. Extracellular matrix binding mixed micelles for drug delivery applications.
    J Control Release, 137(2): 146-51. [Abstract] [Full-text]
70. Surface engineering of microparticles by novel protein transfer for targeted antigen/drug delivery.
    J Control Release, 137(2): 90-7. [Abstract] [Full-text]
71. Prehospital intraosseus access with the bone injection gun by a helicopter-transported emergency medical team.
    J Trauma, 66(6): 1739-41. [Abstract] [Full-text]
72. Anti-inflammatory resuscitation improves survival in hemorrhage with trauma.
    J Trauma, 66(6): 1632-9; discussion 1639-40. [Abstract] [Full-text]
73. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
    Br J Cancer, 100(12): 1842-5. [Abstract] [Full-text]
74. Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer.
    Br J Cancer, 100(12): 1861-6. [Abstract] [Full-text]
75. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.
    Proc Natl Acad Sci U S A, 106(23): 9403-8. [Abstract] [Full-text]
76. Haematodermic CD4+CD56+ neoplasm: complete remission after methotrexate-asparaginase treatment.
    Clin Exp Dermatol, 34(5): e43-5. [Abstract] [Full-text]
77. Polyelectrolyte nanoparticles based on water-soluble chitosan-poly(L-aspartic acid)-polyethylene glycol for controlled protein release.
    Carbohydr Res, 344(10): 1197-204. [Abstract] [Full-text]
78. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
    Science, 324(5933): 1457-61. [Abstract] [Full-text]
79. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
    Blood, 113(24): 6069-76. [Abstract] [Full-text]
80. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Blood, 113(24): 6077-84. [Abstract] [Full-text]
81. Polymeric nanomedicine for cancer MR imaging and drug delivery.
    Chem Commun (Camb). [Abstract] [Full-text]
82. Management of limb ischaemia in the neonate and infant.
    Eur J Vasc Endovasc Surg, 38(1): 61-5. [Abstract] [Full-text]
83. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
    Am J Respir Cell Mol Biol, 41(1): 14-23. [Abstract] [Full-text]
84. Reproductive history, hormonal factors and the incidence of hip and knee replacement for osteoarthritis in middle-aged women.
    Ann Rheum Dis, 68(7): 1165-70. [Abstract] [Full-text]
85. Preliminary in vitro evaluation of an adjunctive therapy for extremity wound infection reduction: rapidly resorbing local antibiotic delivery.
    J Orthop Res, 27(7): 903-8. [Abstract] [Full-text]
86. Nanoencapsulation increases quinine antimalarial efficacy against Plasmodium berghei in vivo.
    Int J Antimicrob Agents, 34(2): 156-61. [Abstract] [Full-text]
87. Effects of physicochemical properties of salting-out layer components on drug release.
    Int J Pharm, 376(1): 13-21. [Abstract] [Full-text]
88. Evaluation of the mechanical properties and drug release of cross-linked Eudragit films containing metronidazole.
    Int J Pharm, 376(1): 1-6. [Abstract] [Full-text]
89. Heparin-functionalized chitosan-alginate scaffolds for controlled release of growth factor.
    Int J Pharm, 376(1): 69-75. [Abstract] [Full-text]
90. Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts.
    Drug Alcohol Depend, 103(3): 107-13. [Abstract] [Full-text]
91. Route of administration influences substitution patterns in rats trained to discriminate methadone vs. vehicle.
    Drug Alcohol Depend, 103(3): 124-30. [Abstract] [Full-text]
92. Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug delivery.
    Int J Pharm, 376(1): 195-203. [Abstract] [Full-text]
93. Chemical stability and phase distribution of all-trans-retinol in nanoparticle-coated emulsions.
    Int J Pharm, 376(1): 186-94. [Abstract] [Full-text]
94. Facile fabrication of well-defined hydrogel beads with magnetic nanocomposite shells.
    Int J Pharm, 376(1): 92-8. [Abstract] [Full-text]
95. Chitosan solutions and particles: evaluation of their permeation enhancing potential on MDCK cells used as blood brain barrier model.
    Int J Pharm, 376(1): 104-9. [Abstract] [Full-text]
96. Hyperbranched polysiloxysilane nanoparticles: surface charge control of nonviral gene delivery vectors and nanoprobes.
    Int J Pharm, 376(1): 141-52. [Abstract] [Full-text]
97. A new micro/nanoencapsulated porphyrin formulation for PDT treatment.
    Int J Pharm, 376(1): 76-83. [Abstract] [Full-text]
98. Micronization of silybin by the emulsion solvent diffusion method.
    Int J Pharm, 376(1): 116-22. [Abstract] [Full-text]
99. Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization.
    Int J Pharm, 376(1): 176-85. [Abstract] [Full-text]
100. Nanoparticle formation from probucol/PVP/sodium alkyl sulfate co-ground mixture.
     Int J Pharm, 376(1): 169-75. [Abstract] [Full-text]
101. Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles.
     Int J Pharm, 376(1): 161-8. [Abstract] [Full-text]
102. Development of PMMA membranes functionalized with hydroxypropyl-beta-cyclodextrins for controlled drug delivery using a supercritical CO(2)-assisted technology.
     Int J Pharm, 376(1): 110-5. [Abstract] [Full-text]
103. pH-sensitive properties of surface charge-switched multifunctional polymeric micelle.
     Int J Pharm, 376(1): 134-40. [Abstract] [Full-text]
104. Approach to design push-pull osmotic pumps.
     Int J Pharm, 376(1): 56-62. [Abstract] [Full-text]
105. The complexation between novel comb shaped amphiphilic polyallylamine and insulin: towards oral insulin delivery.
     Int J Pharm, 376(1): 46-55. [Abstract] [Full-text]
106. Synthesis of cationic derivatives of Quil A and the preparation of cationic immune-stimulating complexes (ISCOMs).
     Int J Pharm, 376(1): 123-33. [Abstract] [Full-text]
107. Evaluation of antibiotic prophylaxis in reducing postoperative infection after mandibular third molar extraction in young patients.
     J Oral Maxillofac Surg, 67(7): 1467-72. [Abstract] [Full-text]
108. Current issues in prevention of mother-to-child transmission of HIV-1.
     Curr Opin HIV AIDS, 4(4): 319-24. [Abstract] [Full-text]
109. The encapsulation and intracellular delivery of trehalose using a thermally responsive nanocapsule.
     Nanotechnology, 20(27): 275101. [Abstract] [Full-text]
110. A mesoporous silica nanosphere-based drug delivery system using an electrically conducting polymer.
     Nanotechnology, 20(27): 275102. [Abstract] [Full-text]
111. Evaluation of universal antenatal screening for group B streptococcus.
     N Engl J Med, 360(25): 2626-36. [Abstract] [Full-text]
112. Intravascular flow patterns in transforaminal epidural injections: a comparative study of the cervical and lumbar vertebral segments.
     Anesth Analg, 109(1): 233-9. [Abstract] [Full-text]
113. Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases.
     Surgery, 146(1): 52-9. [Abstract] [Full-text]
114. Association of Thrombolysis in Myocardial Infarction Myocardial Perfusion Grade with cardiovascular magnetic resonance measures of infarct architecture after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
     Am Heart J, 158(1): 84-91. [Abstract] [Full-text]
115. Potential reductions in United States coronary heart disease mortality by treating more patients.
     Am J Cardiol, 103(12): 1703-9. [Abstract] [Full-text]
116. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
     J Clin Oncol, 27(18): 3007-13. [Abstract] [Full-text]
117. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
     J Clin Oncol, 27(18): 3014-9. [Abstract] [Full-text]
118. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings.
     Clin Infect Dis, 49(2): 306-9. [Abstract] [Full-text]
119. Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut.
     Clin Infect Dis, 49(2): 262-70. [Abstract] [Full-text]
120. In vitro macrophage uptake and in vivo biodistribution of long-circulation nanoparticles with poly(ethylene-glycol)-modified PLA (BAB type) triblock copolymer.
     Colloids Surf B Biointerfaces, 72(2): 303-11. [Abstract] [Full-text]
121. Design and influence of gamma-irradiation on the biopharmaceutical properties of nanoparticles containing an antigenic complex from Brucella ovis.
     Eur J Pharm Sci, 37(5): 563-72. [Abstract] [Full-text]
122. Influence of structural variations on drug release from lipid/polyethylene glycol matrices.
     Eur J Pharm Sci, 37(5): 555-62. [Abstract] [Full-text]
123. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
     Cancer Lett, 281(2): 171-82. [Abstract] [Full-text]
124. Complement upregulation in photodynamic therapy-treated tumors: Role of Toll-like receptor pathway and NFkappaB.
     Cancer Lett, 281(2): 232-8. [Abstract] [Full-text]
125. Comparison of primary percutaneous coronary intervention and fibrinolytic therapy in ST-segment-elevation myocardial infarction: bayesian hierarchical meta-analyses of randomized controlled trials and observational studies.
     Circulation, 119(24): 3101-9. [Abstract] [Full-text]
126. Endovascular repair of infrarenal abdominal aortic aneurysm associated with a horseshoe kidney and graft thrombosis in early follow-up.
     Acta Radiol, 50(6): 624-8. [Abstract] [Full-text]
127. Statins for all: the new premed?
     Br J Anaesth, 103(1): 99-107. [Abstract] [Full-text]
128. What are next generation innovative therapeutic targets? Clues from genetic, structural, physicochemical, and systems profiles of successful targets.
     J Pharmacol Exp Ther, 330(1): 304-15. [Abstract] [Full-text]
129. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
     Int J Radiat Oncol Biol Phys, 74(4): 1006-11. [Abstract] [Full-text]
130. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
     Int J Radiat Oncol Biol Phys, 74(4): 1108-13. [Abstract] [Full-text]
131. Pattern electroretinographic results after photodynamic therapy alone and photodynamic therapy in combination with intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
     Doc Ophthalmol, 119(1): 37-42. [Abstract] [Full-text]
132. Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
     Doc Ophthalmol, 119(1): 29-36. [Abstract] [Full-text]
133. A drug-eluting contact lens.
     Invest Ophthalmol Vis Sci, 50(7): 3346-52. [Abstract] [Full-text]
134. Suppression of shivering during hypothermia using a novel drug combination in healthy volunteers.
     Anesthesiology, 111(1): 110-5. [Abstract] [Full-text]
135. Treating childhood acute lymphoblastic leukemia without cranial irradiation.
     N Engl J Med, 360(26): 2730-41. [Abstract] [Full-text]
136. Routine early angioplasty after fibrinolysis for acute myocardial infarction.
     N Engl J Med, 360(26): 2705-18. [Abstract] [Full-text]
137. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
     Jpn J Clin Oncol, 39(7): 449-55. [Abstract] [Full-text]
138. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.
     Am J Epidemiol, 170(1): 12-23. [Abstract] [Full-text]
139. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
     Am J Epidemiol, 170(1): 24-8. [Abstract] [Full-text]
140. Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan Clinical Oncology Group Study (JCOG0706).
     Jpn J Clin Oncol, 39(7): 460-3. [Abstract] [Full-text]
141. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.
     Jpn J Clin Oncol, 39(7): 443-8. [Abstract] [Full-text]
142. Relapse with malignant transformation after chemotherapy for primary mediastinal seminoma: case report.
     Jpn J Clin Oncol, 39(7): 456-9. [Abstract] [Full-text]
143. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
     Jpn J Clin Oncol, 39(7): 418-24. [Abstract] [Full-text]
144. Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
     Jpn J Clin Oncol, 39(7): 413-7. [Abstract] [Full-text]
145. The success of primary chemotherapy for group D heritable retinoblastoma.
     Br J Ophthalmol, 93(7): 887-90. [Abstract] [Full-text]
146. Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors.
     Invest New Drugs, 27(4): 356-65. [Abstract] [Full-text]
147. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
     Invest New Drugs, 27(4): 366-73. [Abstract] [Full-text]
148. Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines.
     Invest New Drugs, 27(4): 297-303. [Abstract] [Full-text]
149. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.
     Lancet Infect Dis, 9(7): 409-17. [Abstract] [Full-text]
150. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.
     Cancer Invest, 27(6): 636-40. [Abstract] [Full-text]
151. Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation.
     Cancer Invest, 27(6): 624-35. [Abstract] [Full-text]
152. Unintended consequence of plant transformation: biolistic transformation caused transpositional activation of an endogenous retrotransposon Tos17 in rice ssp. japonica cv. Matsumae.
     Plant Cell Rep, 28(7): 1043-51. [Abstract] [Full-text]
153. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations.
     Am J Kidney Dis, 54(1): 33-42. [Abstract] [Full-text]
154. Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.
     Gynecol Oncol, 114(2): 206-9. [Abstract] [Full-text]
155. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients.
     Cancer, 115(13): 2980-7. [Abstract] [Full-text]
156. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer.
     Cancer, 115(13): 2999-3008. [Abstract] [Full-text]
157. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
     Gynecol Oncol, 114(2): 242-5. [Abstract] [Full-text]
158. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
     Gynecol Oncol, 114(2): 210-4. [Abstract] [Full-text]
159. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
     Gynecol Oncol, 114(2): 215-8. [Abstract] [Full-text]
160. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
     Gynecol Oncol, 114(2): 253-9. [Abstract] [Full-text]
161. IgE-mediated allergen gene vaccine platform targeting human antigen-presenting cells through the high-affinity IgE receptor.
     J Allergy Clin Immunol, 124(1): 108-13. [Abstract] [Full-text]
162. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part II. What are the criteria to predict involved lymph nodes?
     Radiology, 252(1): 81-91. [Abstract] [Full-text]
163. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part I. Are we able to predict tumor confined to the rectal wall?
     Radiology, 252(1): 71-80. [Abstract] [Full-text]
164. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
     Cancer, 115(13): 2964-70. [Abstract] [Full-text]
165. High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome.
     Cancer, 115(13): 2956-63. [Abstract] [Full-text]
166. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study.
     Eur J Endocrinol, 161(1): 119-30. [Abstract] [Full-text]
167. Histologic and manometric studies on the esophagus following endoscopic sclerotherapy.
     Dig Dis Sci, 54(8): 1713-9. [Abstract] [Full-text]
168. Persistence of androgenic effects on the production of proinflammatory cytokines by circulating antigen-presenting cells after withdrawal of testosterone treatment in aging type 2 diabetic men with partial androgen deficiency.
     Fertil Steril, 92(1): 311-9. [Abstract] [Full-text]
169. Enhanced neuroactivation during verbal memory processing in postmenopausal women receiving short-term hormone therapy.
     Fertil Steril, 92(1): 197-204. [Abstract] [Full-text]
170. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
     J Med Virol, 81(8): 1323-35. [Abstract] [Full-text]
171. Preparation and properties of hydroxycamptothecin-loaded nanoparticles made of amphiphilic copolymer and normal polymer.
     J Colloid Interface Sci, 336(2): 808-13. [Abstract] [Full-text]
172. An audit of prophylactic antibiotic use in laryngeal reconstruction surgery.
     Int J Pediatr Otorhinolaryngol, 73(8): 1157-9. [Abstract] [Full-text]
173. Preparation of an amphiphilic triblock copolymer with pH- and thermo-responsiveness and self-assembled micelles applied to drug release.
     J Colloid Interface Sci, 336(2): 865-71. [Abstract] [Full-text]
174. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
     Lung Cancer, 65(2): 192-7. [Abstract] [Full-text]
175. Peripheral benzodiazepine receptor ligand-PLGA polymer conjugates potentially useful as delivery systems of apoptotic agents.
     J Control Release, 137(3): 185-95. [Abstract] [Full-text]
176. Tailor-made dissolution profiles by extruded matrices based on lipid polyethylene glycol mixtures.
     J Control Release, 137(3): 211-6. [Abstract] [Full-text]
177. A new class of inhibitors of peptide sorption and acylation in PLGA.
     J Control Release, 137(3): 179-84. [Abstract] [Full-text]
178. Dietary chemoprevention strategies for induction of phase II xenobiotic-metabolizing enzymes in lung carcinogenesis: A review.
     Lung Cancer, 65(2): 129-37. [Abstract] [Full-text]
179. A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.
     Lung Cancer, 65(2): 187-91. [Abstract] [Full-text]
180. Selective pulmonary artery perfusion for the treatment of primary lung cancer: Improved drug exposure of the lung.
     Lung Cancer, 65(2): 208-13. [Abstract] [Full-text]
181. UHMWPE carrying estradiol to treat the particle-induced osteolysis-Processing and characterizing.
     J Biomed Mater Res A, 90(2): 496-505. [Abstract] [Full-text]
182. pH-dependent self-assembling behavior of imidazole-containing polyaspartamide derivatives.
     J Biomed Mater Res A, 90(2): 478-86. [Abstract] [Full-text]
183. Controlled delivery of paclitaxel from stent coatings using novel styrene maleic anhydride copolymer formulations.
     J Biomed Mater Res A, 90(2): 522-32. [Abstract] [Full-text]
184. Better posttransplant outcome with fludarabine based conditioning in multitransfused fanconi anemia patients who underwent peripheral blood stem cell transplantation.
     J Pediatr Hematol Oncol, 31(7): 512-5. [Abstract] [Full-text]
185. 'Injecting' yeast.
     Nat Methods, 6(7): 513-4. [Abstract] [Full-text]
186. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
     J Clin Oncol, 27(19): 3109-16. [Abstract] [Full-text]
187. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
     J Clin Oncol, 27(19): 3117-25. [Abstract] [Full-text]
188. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
     J Clin Oncol, 27(19): 3217-24. [Abstract] [Full-text]
189. Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
     J Clin Oncol, 27(19): 3185-91. [Abstract] [Full-text]
190. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR).
     Stroke, 40(7): 2442-9. [Abstract] [Full-text]
191. Gender differences in acute ischemic stroke: etiology, stroke patterns and response to thrombolysis.
     Stroke, 40(7): 2428-32. [Abstract] [Full-text]
192. Blood volume measurement to guide fluid therapy after aneurysmal subarachnoid hemorrhage: a prospective controlled study.
     Stroke, 40(7): 2575-7. [Abstract] [Full-text]
193. Is it time to reassess the SITS-MOST criteria for thrombolysis?: A comparison of patients with and without SITS-MOST exclusion criteria.
     Stroke, 40(7): 2568-71. [Abstract] [Full-text]
194. Clinical-diffusion mismatch and benefit from thrombolysis 3 to 6 hours after acute stroke.
     Stroke, 40(7): 2572-4. [Abstract] [Full-text]
195. Facile fabrication method and characterization of hollow Ag/SiO2 double-shelled spheres.
     Langmuir, 25(13): 7646-51. [Abstract] [Full-text]
196. Carboxyl enriched monodisperse porous Fe3O4 nanoparticles with extraordinary sustained-release property.
     Langmuir, 25(13): 7244-8. [Abstract] [Full-text]
197. Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception.
     Adv Drug Deliv Rev, 61(10): 808-12. [Abstract] [Full-text]
198. Drug delivery for in vitro fertilization: rationale, current strategies and challenges.
     Adv Drug Deliv Rev, 61(10): 871-82. [Abstract] [Full-text]
199. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers.
     Adv Drug Deliv Rev, 61(10): 768-84. [Abstract] [Full-text]
200. Current challenges in clinical management of endometrial cancer.
     Adv Drug Deliv Rev, 61(10): 883-9. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.